ELF3 and Fabry disease: These benefits suggest a potential role for SGLT2i in FD patients with CKD as these drugs could target the FD pathogenetic mechanisms, such as oxidative stress and inflammation, which are not completely addressed by ERT or chaperon therapy alone.